Global Celiac Disease Market Insight, Epidemiology and Market Forecast Report 2017-2020 & 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Celiac Disease (CD) Market Insight, Epidemiology and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This ‘Celiac Disease (CD) – Market Insights, Epidemiology and Market Forecast- 2030’ report delivers an in-depth understanding of the Celiac Disease (CD), historical and forecasted epidemiology as well as the Celiac Disease (CD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Findings

• The total prevalent population of Celiac Disease in the 7 major markets was 6,450,607 in 2020 which is anticipated to increase at a CAGR of 0.53% during the study period (2018-2030).
• The total 7MM diagnosed prevalent cases of Celiac Disease in 2020 were 1,403,779 out of which the highest diagnosed prevalent cases of this disease were in the United States, which was 701,718 which is anticipated to increase at a CAGR of 2.0% during the study period (2018-2030).
• According to the estimates by the publisher, 252,618 and 449,099 cases of males and females were in the United States, in 2020.
• In the United States, the number of cases of Classical, Non-classical and Sub-clinical were 189,464, 364,893 and 147,361 respectively, in 2020.
• In the United States the maximum number of cases of Celiac Disease were in the age group of 19-39 with 256,127 cases in 2020, while the lowest number of cases were in the age group >80 with 14,034 cases in 2020.
• In the EU5 countries the total prevalent population of Celiac Disease was maximum in Germany with 742,796 cases, followed by the United Kingdom with 660,156 cases in 2020. While, the least number of cases were in Spain, i.e., 430,359 in 2020.
• In Japan, the prevalence of Celiac Disease was 66,130 in 2020.

Key Topics Covered:

1 Key Insights

2 Celiac Disease Market Overview at a Glance

2.1 Market Share (%) Distribution of Celiac Disease in 2018

2.2 Market Share (%) Distribution of Celiac Disease in 2030

3 Executive Summary of Celiac Disease (CD)

4 Disease Background and Overview: Celiac Disease

4.1 Introduction

4.2 Types

4.2.1 Classical CD

4.2.2 Non-Classical CD

4.2.3 Silent CD

4.3 Causes

4.3.1 Genetics Factors

4.3.2 Environmental Factors

4.4 Symptoms

4.5 Pathogenesis

4.6 Pathophysiology

4.6.1 Genetics

4.6.2 Gluten, as an environmental trigger of CD

4.7 Clinical Presentation

4.8 Diagnosis

4.8.1 Diagnostic Tests of CD

4.9 Biomarkers for CD

4.9.1 Genetic Biomarkers in CD

4.9.2 Serological Biomarkers in CD

4.10 Differential diagnosis

5 Algorithm for Diagnosis of CD

6 Diagnostic Guidelines by the European Society for the Study of Coeliac Disease (ESsCD)

6.1 Recommendations on who should be tested for CD

6.2 Recommendations for Serology

6.3 Recommendations for Endoscopy and Histopathology

6.4 Recommendations for HLA-DQ2/8 Typing

6.5 Recommendations for other Diagnostic Tests

6.6 Recommendations for Diagnostic Confirmation

7 Diagnostic Guidelines by the World Gastroenterology Organization (WGO)

7.1 Recommendation for Diagnosis

7.2 Recommendations for Testing Patients

7.2.1 Patients with clinical manifestations suggestive of CD

7.2.2 Conditions associated with an increased risk for CD

7.2.3 First-degree relatives of patients with CD

7.3 Recommendations for Diagnostic Tests

7.3.1 Endoscopy in patients with suspected CD

7.3.2 Intestinal biopsy and histology

7.3.3 Serum antibody tests

8 Epidemiology and Patient Population: Key Findings

8.1 7MM Total Prevalent Population of Celiac Disease

8.2 MM Total Diagnosed Prevalent Population of Celiac Disease

9 Country Wise-Epidemiology of Celiac Disease

9.1 United States

9.2 EU5 Countries

9.3 Germany

9.4 France

9.5 Italy

9.6 Spain

9.7 United Kingdom

9.8 Japan

10 Treatment

10.1 Gluten-free Diet (GFD)

10.1.1 Gluten-free (GF) foods on prescription

10.1.2 Oats

10.2 Other treatments

10.2.1 Vaccinations

10.2.2 Supplements

10.2.3 Pharmacologic Treatments

10.2.4 Gluten-degrading enzymes

10.2.5 Blocking gluten entry across the intestinal epithelium

10.2.6 Rho/Rho-kinase inhibition

10.2.7 Immunotherapy

10.2.8 Dermatitis Herpetiformis

10.3 Refractory Celiac Disease (RCD)

11 Treatment Algorithm for CD

12 Treatment Algorithm for CD by BMJ Best Practice

12.1 Gluten-free diet (1st Line Treatment)

12.1.1 Calcium and Vitamin D supplementation with or without Iron

12.2 Refractory Celiac Disease (RCD)

12.3 Celiac Crisis

12.3.1 Rehydration and correction of electrolyte abnormalities

12.3.2 Corticosteroid adjunct treatment

13 European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders

13.1 Dietary Management

13.2 Follow Up

13.3 Slow-responders and RCD

13.3.1 Recommendations for treating RCD-I

13.3.2 Recommendations for treating RCD-II

13.4 Special Issues about Children and Adolescents

14 World Gastroenterology Organisation Global Guidelines for CD

15 Recognized Establishments

16 Unmet Needs

17 Emerging Drugs

17.1 Key Cross Competition

17.2 Larazotide Acetate (INN-202/AT-1001): 9 Meters Biopharma

17.3 Latiglutenase (IMGX003/ALV003): ImmunogenX

17.4 PRV-015: Provention Bio

17.5 TAK-101: Takeda/Cour Pharmaceuticals

17.6 AG017: Precigen ActoBio

17.7 ZED1227: Falk Pharma and Zedira

18 Celiac Disease: 7 Major Market Analysis

19 The United States Market Outlook

20 EU-5 Countries: Market Outlook

21 Japan Market Outlook

22 KOL Reviews

23 Case Reports

23.1 Association of gluten intake during the first 5 years of life with the incidence of celiac disease autoimmunity and celiac disease among children at increased risk (US)

23.2 The prevalence of the celiac disease in Europe: Results of a centralized, international mass screening project (Italy)

23.3 A case of celiac disease with type I enteropathy-associated T-cell lymphoma in a Japanese male patient (Japan)

24 Market Drivers

25 Market Barriers

26 SWOT Analysis

27 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dquaq

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900